Novogen Ltd (NVGN) 3.94 $NVGN
Children's Oncology Drug Alliance (CODA) Formed to Facilitate Development of Treatments for Childhood Cancers
PR Newswire - Sun May 04, 5:19PM CDT
Researchers and children's cancer advocates in Australia and the U.S. have formed a unique research and development alliance to facilitate development of treatments for children fighting neuroblastoma, the most common and fatal form of solid cancer affecting infants.
Novogen and Genea Announce Partnership to Investigate Promising New Approach to Neurodegenerative Diseases
PR Newswire - Fri May 02, 8:27AM CDT
Novogen Limited (NASDAQ: NVGN, ASX: NRT
, an oncology drug development company, today announced a collaboration with Australian company, Genea Biocells, to accelerate testing of their super-benzopyran (SBP) drugs for degenerative diseases of the nervous system and muscles.
Novogen and CanTx's experimental drug Trx-1 passes important test to fight abdominal cancers
M2 - Wed Mar 19, 7:56AM CDT
Australian biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) revealed on Tuesday that its lead candidate drug, Trx-1, has demonstrated a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells in partnership with CanTx.
Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo
PR Newswire - Tue Mar 18, 7:00AM CDT
Novogen Limited [ASX:NRT; NASDAQ:NVGN] and its joint venture company with Yale University, CanTx Inc, today announced an important milestone with lead candidate drug, Trx-1, demonstrating a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells.
Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
PR Newswire - Wed Mar 12, 10:00AM CDT
Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced that Graham Kelly, Ph.D., Executive Director and Chief Executive Officer, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum. Dr. Kelly's presentation will take place at 2:30 p.m. on Wednesday, March 19, 2014 at the New York Academy of Sciences in New York City.
Novogen Selected to Present at Cavendish Global Health Impact Forum
PR Newswire - Mon Mar 10, 12:27PM CDT
Novogen Limited (ASX: 'NRT'; NASDAQ: 'NVGN' , an oncology drug development company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 at the United Nations Headquarters in New York. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.
Novogen Appoints New Board Members and Strategic Advisor to Support Transition to Clinical Development and Growing International Presence
PR Newswire - Tue Mar 04, 5:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN]), an oncology drug development company, today announced key new appointments to guide the company in its transition into a clinical-stage company with a growing U.S. presence and an investor base in the U.S. and Australia. Professor Peter Gunning, PhD, a leading world authority on the cytoskeleton, and Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive, join the Novogen board of directors as non-executive directors. David W. Gryska, an industry expert with over 20 years of experience in management at many of the top U.S. biotechnology companies, will serve as a strategic advisor to the board with a focus on U.S. capital markets and as a U.S. shareholder liaison.
New Sears Appliance & Hardware Store Opens in Huntsville
GlobeNewswire - Fri Feb 21, 2:30PM CST
Sears Hometown and Outlet Stores, Inc. (Nasdaq:SHOS) announces the opening of a new Sears Appliance & Hardware Store located at 1702 11 Street in Huntsville, Texas.
Direct Energy Revenue Up 28% in 2013
PR Newswire - Thu Feb 20, 1:15AM CST
Direct Energy, North America's largest competitive energy and energy-related services company, today announced gross revenue for the full year 2013 of US $11.4 billion (£7.3 billion), an increase of 28 percent, and an operating profit of US$436 million (£276 million). Direct Energy is the North American subsidiary of Centrica plc (LSE: CNA). Centrica reported full year 2013 revenues of US$41.6 billion (£26.6 billion) with an operating profit of US$4.2 billion (£2.7 billion).
Novogen Announces Key Appointments to Drive Development of Anti-Tropomyosin Drug Platform
PR Newswire - Mon Feb 03, 11:30AM CST
Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced the appointments of Justine Stehn, PhD and Professor Peter Gunning, PhD to roles within the Company. Dr. Stehn and Professor Gunning are the co-inventors of the anti-tropomyosin (ATM) drug technology platform that Novogen acquired in 2013, and their appointments are an important step in realizing the significant potential of this new drug platform in treating cancer.
Novogen to Host Corporate Update and Webcast
PR Newswire - Thu Jan 30, 5:54PM CST
Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced it will host a corporate update with Graham Kelly, Ph.D., Novogen Group Executive Chairman and Chief Executive Officer, and David Brown, Ph.D., Chief Scientific Officer on Friday, February 7, 2014 at 8:00 a.m. (Sydney local time). This corresponds to Thursday, February 6, 2014 at 4:00 p.m. U.S. Eastern Standard Time.
Novogen to Present at Biotech Showcase(TM) 2014
PR Newswire - Wed Jan 08, 6:30AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN), an oncology drug development company, today announced that Graham Kelly, Ph.D., its Executive Chairman and Chief Executive Officer, is scheduled to present a company overview to investors, pharmaceutical and healthcare executives attending the Biotech Showcase(TM) 2014, taking place January 13-15, 2014 in San Francisco, Calif.
Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer
PR Newswire - Fri Dec 20, 7:00AM CST
Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma multiforme (GBM).
Novogen files suite of patents in US for ATM drug technology
M2 - Wed Nov 27, 4:23AM CST
Australian biotechnology company Novogen Limited (ASX: NRT)(Nasdaq:NVGN) announced on Tuesday the filing of a family of provisional patents in the US covering anti-tropomyosin (ATM) drug technology.
Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology
PR Newswire - Tue Nov 26, 7:42AM CST
Novogen Limited (ASX: symbol NRT; Nasdaq: symbol NVGN) today announced the filing of a family of provisional patents in the US covering anti-tropomyosin (ATM) drug technology.
HIMX, GALE, INTC and NVGN added to NASDAQ Active Stock Watch List at GSR
ACCESSWIRE - Mon Nov 25, 9:16AM CST
New York, NY - (ACCESSWIRE) - 11/25/2013 - Growing Stock Report initiates its NASDAQ Active Stock Weekly Watch List adding Himax Technologies, Inc. (NASDAQ:HIMX), Galena Biopharma, Inc. (NASDAQ:GALE), Intel Corporation (NASDAQ:INTC) and Novogen Limited (NASDAQ:NVGN)
Market Maker Surveillance Report. CKSW, NVGN, USU, NDLS, DQ, RNDY, Losing Stocks With Lowest Price Friction For Monday, July 8th 2013
M2 - Tue Jul 09, 4:23AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3901 companies with "abnormal" market making, 2937 companies with positive Friction Factors and 2297 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Clicksoftware Technologies Ltd (NASDAQ:CKSW), Novogen Ltd (NASDAQ:NVGN), USEC Inc (NYSE:USU), NATIONAL DLR STORES (NASDAQ:NDLS), Daqo New Energy Corp (NYSE
Q), Roundy's Inc (NYSE:RNDY). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks
Market Maker Surveillance Report. NURO, NVGN, ET, LOTE, INFI, BEAT, Winning Stocks With Lowest Price Friction For Tuesday, June 4th 2013
M2 - Wed Jun 05, 3:30AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3819 companies with "abnormal" market making, 2025 companies with positive Friction Factors and 3252 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. NeuroMetrix Inc (NASDAQ:NURO), Novogen Ltd (NASDAQ:NVGN), E*TRADE FINL CORP (NYSE:ET), LORIMAR TELEPICTURES (OTC:LOTE), Infinity Pharmaceuticals Inc (NASDAQ:INFI), CardioNet Inc (NASDAQ:BEAT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
NVGN, AVEO, QQEW, Removed From Naked Short Lists Today
M2 - Mon May 20, 8:54AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), Aveo Pharmaceuticals Inc (NASDAQ:AVEO), First Trust Portfolios LP (NASDAQ:QQEW). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
NVGN, ABIO, RVXCF, QQEW, Added To Naked Short Lists Today
M2 - Thu May 09, 8:54AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), ARCA Biopharma Inc (NASDAQ:ABIO), RESVERLOGIX CORP (OTC:RVXCF), First Trust Portfolios LP (NASDAQ:QQEW). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
Children's Oncology Drug Alliance (CODA) Formed to Facilitate Development of Treatments for Childhood Cancers
PR Newswire - Sun May 04, 5:19PM CDT
Researchers and children's cancer advocates in Australia and the U.S. have formed a unique research and development alliance to facilitate development of treatments for children fighting neuroblastoma, the most common and fatal form of solid cancer affecting infants.
Novogen and Genea Announce Partnership to Investigate Promising New Approach to Neurodegenerative Diseases
PR Newswire - Fri May 02, 8:27AM CDT
Novogen Limited (NASDAQ: NVGN, ASX: NRT
, an oncology drug development company, today announced a collaboration with Australian company, Genea Biocells, to accelerate testing of their super-benzopyran (SBP) drugs for degenerative diseases of the nervous system and muscles. Novogen and CanTx's experimental drug Trx-1 passes important test to fight abdominal cancers
M2 - Wed Mar 19, 7:56AM CDT
Australian biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) revealed on Tuesday that its lead candidate drug, Trx-1, has demonstrated a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells in partnership with CanTx.
Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo
PR Newswire - Tue Mar 18, 7:00AM CDT
Novogen Limited [ASX:NRT; NASDAQ:NVGN] and its joint venture company with Yale University, CanTx Inc, today announced an important milestone with lead candidate drug, Trx-1, demonstrating a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells.
Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
PR Newswire - Wed Mar 12, 10:00AM CDT
Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced that Graham Kelly, Ph.D., Executive Director and Chief Executive Officer, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum. Dr. Kelly's presentation will take place at 2:30 p.m. on Wednesday, March 19, 2014 at the New York Academy of Sciences in New York City.
Novogen Selected to Present at Cavendish Global Health Impact Forum
PR Newswire - Mon Mar 10, 12:27PM CDT
Novogen Limited (ASX: 'NRT'; NASDAQ: 'NVGN'
, an oncology drug development company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 at the United Nations Headquarters in New York. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. Novogen Appoints New Board Members and Strategic Advisor to Support Transition to Clinical Development and Growing International Presence
PR Newswire - Tue Mar 04, 5:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN]), an oncology drug development company, today announced key new appointments to guide the company in its transition into a clinical-stage company with a growing U.S. presence and an investor base in the U.S. and Australia. Professor Peter Gunning, PhD, a leading world authority on the cytoskeleton, and Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive, join the Novogen board of directors as non-executive directors. David W. Gryska, an industry expert with over 20 years of experience in management at many of the top U.S. biotechnology companies, will serve as a strategic advisor to the board with a focus on U.S. capital markets and as a U.S. shareholder liaison.
New Sears Appliance & Hardware Store Opens in Huntsville
GlobeNewswire - Fri Feb 21, 2:30PM CST
Sears Hometown and Outlet Stores, Inc. (Nasdaq:SHOS) announces the opening of a new Sears Appliance & Hardware Store located at 1702 11 Street in Huntsville, Texas.
Direct Energy Revenue Up 28% in 2013
PR Newswire - Thu Feb 20, 1:15AM CST
Direct Energy, North America's largest competitive energy and energy-related services company, today announced gross revenue for the full year 2013 of US $11.4 billion (£7.3 billion), an increase of 28 percent, and an operating profit of US$436 million (£276 million). Direct Energy is the North American subsidiary of Centrica plc (LSE: CNA). Centrica reported full year 2013 revenues of US$41.6 billion (£26.6 billion) with an operating profit of US$4.2 billion (£2.7 billion).
Novogen Announces Key Appointments to Drive Development of Anti-Tropomyosin Drug Platform
PR Newswire - Mon Feb 03, 11:30AM CST
Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced the appointments of Justine Stehn, PhD and Professor Peter Gunning, PhD to roles within the Company. Dr. Stehn and Professor Gunning are the co-inventors of the anti-tropomyosin (ATM) drug technology platform that Novogen acquired in 2013, and their appointments are an important step in realizing the significant potential of this new drug platform in treating cancer.
Novogen to Host Corporate Update and Webcast
PR Newswire - Thu Jan 30, 5:54PM CST
Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced it will host a corporate update with Graham Kelly, Ph.D., Novogen Group Executive Chairman and Chief Executive Officer, and David Brown, Ph.D., Chief Scientific Officer on Friday, February 7, 2014 at 8:00 a.m. (Sydney local time). This corresponds to Thursday, February 6, 2014 at 4:00 p.m. U.S. Eastern Standard Time.
Novogen to Present at Biotech Showcase(TM) 2014
PR Newswire - Wed Jan 08, 6:30AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN), an oncology drug development company, today announced that Graham Kelly, Ph.D., its Executive Chairman and Chief Executive Officer, is scheduled to present a company overview to investors, pharmaceutical and healthcare executives attending the Biotech Showcase(TM) 2014, taking place January 13-15, 2014 in San Francisco, Calif.
Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer
PR Newswire - Fri Dec 20, 7:00AM CST
Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma multiforme (GBM).
Novogen files suite of patents in US for ATM drug technology
M2 - Wed Nov 27, 4:23AM CST
Australian biotechnology company Novogen Limited (ASX: NRT)(Nasdaq:NVGN) announced on Tuesday the filing of a family of provisional patents in the US covering anti-tropomyosin (ATM) drug technology.
Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology
PR Newswire - Tue Nov 26, 7:42AM CST
Novogen Limited (ASX: symbol NRT; Nasdaq: symbol NVGN) today announced the filing of a family of provisional patents in the US covering anti-tropomyosin (ATM) drug technology.
HIMX, GALE, INTC and NVGN added to NASDAQ Active Stock Watch List at GSR
ACCESSWIRE - Mon Nov 25, 9:16AM CST
New York, NY - (ACCESSWIRE) - 11/25/2013 - Growing Stock Report initiates its NASDAQ Active Stock Weekly Watch List adding Himax Technologies, Inc. (NASDAQ:HIMX), Galena Biopharma, Inc. (NASDAQ:GALE), Intel Corporation (NASDAQ:INTC) and Novogen Limited (NASDAQ:NVGN)
Market Maker Surveillance Report. CKSW, NVGN, USU, NDLS, DQ, RNDY, Losing Stocks With Lowest Price Friction For Monday, July 8th 2013
M2 - Tue Jul 09, 4:23AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3901 companies with "abnormal" market making, 2937 companies with positive Friction Factors and 2297 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Clicksoftware Technologies Ltd (NASDAQ:CKSW), Novogen Ltd (NASDAQ:NVGN), USEC Inc (NYSE:USU), NATIONAL DLR STORES (NASDAQ:NDLS), Daqo New Energy Corp (NYSE
Q), Roundy's Inc (NYSE:RNDY). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks Market Maker Surveillance Report. NURO, NVGN, ET, LOTE, INFI, BEAT, Winning Stocks With Lowest Price Friction For Tuesday, June 4th 2013
M2 - Wed Jun 05, 3:30AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3819 companies with "abnormal" market making, 2025 companies with positive Friction Factors and 3252 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. NeuroMetrix Inc (NASDAQ:NURO), Novogen Ltd (NASDAQ:NVGN), E*TRADE FINL CORP (NYSE:ET), LORIMAR TELEPICTURES (OTC:LOTE), Infinity Pharmaceuticals Inc (NASDAQ:INFI), CardioNet Inc (NASDAQ:BEAT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
NVGN, AVEO, QQEW, Removed From Naked Short Lists Today
M2 - Mon May 20, 8:54AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), Aveo Pharmaceuticals Inc (NASDAQ:AVEO), First Trust Portfolios LP (NASDAQ:QQEW). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
NVGN, ABIO, RVXCF, QQEW, Added To Naked Short Lists Today
M2 - Thu May 09, 8:54AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), ARCA Biopharma Inc (NASDAQ:ABIO), RESVERLOGIX CORP (OTC:RVXCF), First Trust Portfolios LP (NASDAQ:QQEW). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
